Kodiak Sciences (KOD) Cash from Financing Activities (2017 - 2026)
Kodiak Sciences (KOD) reported Cash from Financing Activities of $619000.0 for Q1 2026, up 399.19% on a YoY basis from $124000.0 in Q1 2025, and down 99.65% quarter-over-quarter from $177.2 million in Q4 2025.
Kodiak Sciences (KOD) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Kodiak Sciences has reported Cash from Financing Activities for 10 years, with the latest figure at $619000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 399.19% year-over-year to $619000.0; the trailing twelve-month figure through Mar 2026 stood at $178.8 million (up 30359.45% YoY), and the FY2025 full-year result was $178.3 million, up 35489.22% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $619000.0, down from $177.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $177.2 million in Q4 2025, with the low at -$124000.0 in Q4 2023.
- Historically, Cash from Financing Activities has averaged $11.3 million across 5 years, with a median of $108500.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 227.84% — and 2025, when it soared 43772.52%.
- Kodiak Sciences' Cash from Financing Activities stood at $97000.0 in 2022, then slumped by 227.84% to -$124000.0 in 2023, then surged by 425.81% to $404000.0 in 2024, then soared by 43772.52% to $177.2 million in 2025, then slumped by 99.65% to $619000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $619000.0 (Q1 2026), $177.2 million (Q4 2025), and $813000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 85,464.43 |
| 10 | Kodiak Sciences | 1.95 Bn | 1.95 Bn | - | 619,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 619,000.00 |
| Mar 31, 2026 | 619,000.00 |
| Dec 31, 2025 | 177.25 Mn |
| Dec 31, 2025 | 177.25 Mn |
| Sep 30, 2025 | 813,000.00 |
| Sep 30, 2025 | 813,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 124,000.00 |
| Mar 31, 2025 | 124,000.00 |
| Dec 31, 2024 | 404,000.00 |
| Dec 31, 2024 | 404,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Dec 31, 2023 | -124,000.00 |
| Dec 31, 2023 | -124,000.00 |
| Sep 30, 2023 | -12,000.00 |
| Sep 30, 2023 | -12,000.00 |